Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis

• Main Authors: Rongyi Chen, Lingying Ma, Peng Lv, Jiang Lin, Chaolun Li, Yan Yan, Xuejuan Jin, Xiaomin Dai, Zongfei Ji, Huiyong Chen, Lili Ma, Ying Sun, Lindi Jiang
• Format: Article
• Language: English
• Published: BMC 2021-02-01
• Series: Arthritis Research & Therapy
• Subjects: Complement 3; Takayasu arteritis; Disease activity; Biomarker; C-reactive protein
• Online Access: https://doi.org/10.1186/s13075-021-02433-x

Abstract Background Takayasu arteritis (TA) is a rare disease, lacking convenient and feasible biomarkers to identify disease activity. We aimed to evaluate the value of complements in distinguishing active TA. Methods Consecutive patients were enrolled from the prospective East China TA cohort from April 2008 to June 2019. Patients were divided into two groups according to their baseline Kerr score. The value of complements and other biomarkers in identifying disease activity were analysed with cluster analysis, ROC curves, and combined tests. An independent group of patients from July 2019 to December 2019 were employed to validate the results. Results Of the enrolled 519 patients, 406 (72.2%) cases were identified as active disease. Higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), interleukin-6 (IL-6), and complement 3 (C3) levels were observed in the active group. Elevated C3 (≥ 1.085 g/L) had a high value to identify active TA with a sensitivity of 69.9%, specificity of 66.7%, and AUC of 0.715. Combining the CRP (≥ 10.65 g/L; sensitivity, 50.7%; specificity, 82.4%) and C3, the sensitivity could be improved to 85.1% in parallel test and the specificity could be improved to 94.1% in serial test. Validation was further performed to confirm the value of C3 for disease activity assessment. The accuracy of the parallel test of CRP and C3 in external validation with independent 53 TA cases was 72.73% with the AUC of 0.721. Conclusion Elevated C3 could effectively evaluate the disease activity of TA, and C3 combining with CRP could further improve the disease activity evaluation.